Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor

Biomaterials

Volumn 32, Issue 12, 2011, Pages 3340-3350

  Kuo, Yung Chih ^a   Liang, Cheng Te ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

Anti epithelial growth factor receptor; Carmustine; Catanionic surfactant; Malignant glioblastomas cell; Solid lipid nanoparticle

Indexed keywords

CARMUSTINE; CATANIONIC SURFACTANT; EPITHELIAL GROWTH; GLIOBLASTOMAS; SOLID LIPID NANOPARTICLE;

BRAIN; DISSOLUTION; NANOPARTICLES; PEPTIDES; SURFACE ACTIVE AGENTS; TUMORS; ZETA POTENTIAL;

ENDOTHELIAL CELLS;

CARMUSTINE; CATANIONIC SOLID LIPID NANOPARTICLE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; SOLID LIPID NANOPARTICLE; SURFACTANT; THEOBROMA OIL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIVISION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DISSOLUTION; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ZETA POTENTIAL;

ANIONS; BRAIN NEOPLASMS; CARMUSTINE; CATIONS; CELL DEATH; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIAL CELLS; GLIOBLASTOMA; HUMANS; LIPIDS; MICROSCOPY, FLUORESCENCE; MICROVESSELS; NANOPARTICLES; PARTICLE SIZE; PHOTOELECTRON SPECTROSCOPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; STATIC ELECTRICITY; SURFACE PROPERTIES; SURFACE-ACTIVE AGENTS; TUMOR NECROSIS FACTOR-ALPHA;

THEOBROMA CACAO;

EID: 79951770196     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.01.048     Document Type: Article

References (56)

1. Halatsch M.E., Schmidt U., Behnke-Mursch J., Unterberg A., Wirtz C.R. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 2006, 32:74-89.
2. Argyriou A.A., Antonacopoulou A., Iconomou G., Kalofonos H.P. Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. Crit Rev Oncol Hematol 2009, 69:199-210.
3. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 2001, 37:16-22.
4. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
5. Bramer T., Dew N., Edsman K. Pharmaceutical applications for catanionic mixtures. J Pharm Pharmacol 2007, 59:1319-1334.
6. López-Fontán J.L., Blanco E., Ruso J.M., Prieto M., Schulz P.C., Sarmiento F. The aqueous catanionic system sodium perfl{ligature}uorooctanoate-dodecyltrimethylammonium bromide at low concentration. J Colloid Interface Sci 2007, 312:425-431.
7. Aiello C., Andreozzi P., Mesa C.L., Risuleo G. Biological activity of SDS-CTAB cat-anionic vesicles in cultured cells and assessment of their cytotoxicity ending in apoptosis. Colloids Surf B 2010, 78:149-154.
8. Kuo J.S., Chang C.H., Lin Y.L., Wu C.J. Flow cytometric characterization of interactions between U-937 human macrophages and positively charged catanionic vesicles. Colloids Surf B 2008, 64:307-313.
9. Kuo Y.C., Su F.L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm 2007, 340:143-152.
10. Wong H.L., Bendayan R., Rauth A.M., Li Y., Wu X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007, 59:491-504.
11. Fundarò A., Cavalli R., Bargoni A., Vighetto D., Zara G.P., Gasco M.R. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 2000, 42:337-343.
12. Xu G.W., Nutt C.L., Zlatescu M.C., Keeney M., Chin-Yee I., Cairncross J.G. Inactivation of p53 sensitizes U87MG glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 2001, 61:4155-4159.
13. Sipos E.P., Tyler B., Piantadosi S., Burger P.C., Brem H. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 1997, 39:383-389.
14. Xu X., Chen X., Xu X., Lu T., Wang X., Yang L., et al. BCNU-loaded PEG-PLLA ultrafine fibers and their in vitro antitumor activity against glioma C6 cells. J Control Release 2006, 114:307-316.
15. Vogelhuber W., Spruß T., Bernhardt G., Buschauer A., Göpferich A. Effi{ligature}cacy of BCNU and paclitaxel loaded subcutaneous implants in the interstitial chemotherapy of U-87 MG human glioblastoma xenografts. Int J Pharm 2002, 238:111-121.
16. Weiss R.B., Poster D.S., Penta J.S. The nitrosoureas and pulmonary toxicity. Cancer Treat Rev 1981, 8:111-125.
17. Lohrmann H.P., Lepp K.A., Schreml W. 5-Fluorouracil, 1,3-bis2-chloroethyl.-1-nitrosourea, and 1-2-chloroethyl.-3-4-methylcyclohexyl-1-nitrosourea: effect on the human granulopoietic system. J Natl Cancer Inst 1982, 68:541-547.
18. Bota D.A., Desjardins A., Quinn J.A., Affronti M.L., Friedman H.S. Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas. Ther Clin Risk Manag 2007, 3:707-715.
19. Kuo Y.C. Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int J Pharm 2005, 290:161-172.
20. Maiti K., Bhattacharya S.C., Moulik S.P., Panda A.K. Physicochemistry of the binary interacting mixtures of cetylpyridinium chloride (CPC) and sodium dodecylsulfate (SDS) with special reference to the catanionic ion-pair (coacervate) behavior. Colloids Surf A 2010, 355:88-98.
21. Kuo Y.C., Chen I.C. Evaluation of surface charge density and surface potential by electrophoretic mobility for solid lipid nanoparticles and human brain-microvascular endothelial cells. J Phys Chem B 2007, 111:11228-11236.
22. Kuo Y.C., Lin S.C. Effect of glutamate on the electrical properties of cationic solid lipid nanoparticles containing stearylamine and dioctadecyldimethyl ammonium bromide. J Phys Chem B 2008, 112:4454-4460.
23. Hac-Wydro K., Wydro P. The influence of fatty acids on model cholesterol/phopholipid membranes. Chem Phys Lipids 2007, 150:66-81.
24. Kuo Y.C., Lin C.W. Impact of arginine-modified solid lipid nanoparticles on the membrane charge of human brain-microvascular endothelial cells. Colloids Surf B 2009, 72:201-207.
25. Wan F., You J., Sun Y., Zhang X.G., Cui F.D., Du Y.Z., et al. Studies on PEG-modifi{ligature}ed SLNs loading vinorelbine bitartrate (I): preparation and evaluation in vitro. Int J Pharm 2008, 359:104-110.
26. Kuo Y.C., Lin T.W. Electrophoretic mobility, zeta potential, and fixed charge density of bovine knee chondrocytes, methylmethacrylate-sulfopropylmethacrylate, polybutylcyanoacrylate, and solid lipid nanoparticles. J Phys Chem B 2006, 110:2202-2208.
27. Kuo Y.C., Wang C.C. Electrophoresis of human brain microvascular endothelial cells with uptake of cationic solid lipid nanoparticles: effect of surfactant composition. Colloids Surf B 2010, 76:286-291.
28. Kuo Y.C., Shih K.H. Loading efficiency and surface conductance of heparin-modified poly(lactide-co-glycolide) nanoparticles. Colloids Surf B 2009, 71:282-287.
29. Dubes A., Parrot-Lopez H., Abdelwahed W., Degobert G., Fessi H., Shahgaldian P., et al. Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. Eur J Pharm Biopharm 2003, 55:279-282.
30. Liu J., Gong T., Wang C., Zhong Z., Zhang Z. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharm 2007, 340:153-162.
31. Kuo Y.C., Chiu K.H. Inverted colloidal crystal scaffolds with laminin-derived peptides for neuronal differentiation of bone marrow stromal cells. Biomaterials 2011, 32:819-831.
32. Kuo Y.C., Kuo C.Y. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int J Pharm 2008, 351:271-281.
33. Hou D.Z., Xie C.S., Huang K.J., Zhu C.H. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 2003, 24:1781-1785.
34. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000, 50:161-177.
35. Kuo Y.C., Chen H.H. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int J Pharm 2006, 327:160-169.
36. Souto E.B., Anselmi C., Centini M., Müller R.H. Preparation and characterization of n-dodecyl-ferulate-loaded solid lipid nanoparticles. Int J Pharm 2005, 295:261-268.
37. Kuo Y.C., Lin C.W. Effect of electromagnetic field and surface modification on the electrical behavior of solid lipid nanoparticles covered with L-arginine. Colloids Surf B 2009, 71:45-51.
38. Huang C.C., Su C.H., Li W.M., Liu T.Y., Chen J.H., Yeh C.S. Bifunctional Gd2O3/C nanoshells for MR imaging and NIR therapeutic applications. Adv Funct Mater 2009, 19:249-258.
39. Hu K.W., Huang C.C., Hwu J.R., Su W.C., Shieh D.B., Yeh C.S. A new photothermal therapeutic agent: core-free nanostructured AuxAg1-x dendrites. Chem Eur J 2008, 14:2956-2964.
40. Kuo Y.C., Yeh C.F., Yang J.T. Differentiation of bone marrow stromal cells in poly(lactide-co-glycolide)/chitosan scaffolds. Biomaterials 2009, 30:6604-6613.
41. Zhang L., Radovic-Moreno A.F., Alexis F., Gu F.X., Basto P.A., Bagalkot V., et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2007, 2:1268-1271.
42. Kuo Y.C., Chen H.H. Entrapment and release of saquinavir using cationic solid lipid nanoparticles. Int J Pharm 2009, 365:206-213.
43. Jones C.F., Grainger D.W. In vitro assessments of nanomaterial toxicity. Adv Drug Deliv Rev 2009, 61:438-456.
44. Muller R.H., Maassen S., Weyhers H., Specht F., Lucks J.S. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm 1996, 138:85-94.
45. Kuo Y.C., Chung J.F. Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Colloids Surf B 2011, 83:299-306.
46. Schöler N., Hahn H., Müller R.H., Liesenfeid O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm 2002, 231:167-176.
47. Kuo Y.C., Chen H.H. Effect of electromagnetic field on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells. J Drug Target 2010, 18:447-456.
48. Kuo Y.C., Lin P.I., Wang C.C. Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles. Nanomedicine 2011, accepted.
49. Kim S.B., Ozawa T., Tao H., Umezawa Y. A proinflammatory cytokine sensor cell for assaying inflammatory activities of nanoparticles. Anal Biochem 2007, 362:148-150.
50. Kimura H., Gules I., Meguro T., Zhang J.H. Cytotoxicity of cytokines in cerebral microvascular endothelial cell. Brain Res 2003, 990:148-156.
51. Dutta P.R., Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 2007, 254:165-177.
52. Kuo Y.C., Shih K.H., Yang J.T. Capillary electrophoresis of bone marrow stromal cells with the uptake of heparin-functionalized poly(lactide-co-glycolide) nanoparticles during differentiation towards neurons. Electrophoresis 2010, 31:315-323.
53. Ortiz C., Caja L., Sancho P., Bertran E., Fabregat I. Inhibition of the EGF receptor blocks autocrine growth and increases the cytotoxic effects of doxorubicin in rat hepatoma cells: role of reactive oxygen species production and glutathione depletion. Biochem Pharmacol 2008, 75:1935-1945.
54. Duex J.E., Sorkin A. RNA interference screen identifies Usp18 as a regulator of epidermal growth factor receptor synthesis. Mol Biol Cell 2009, 20:1833-1844.
55. Zhan Y., Counelis G.J., O'Rourke D.M. The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells. Exp Cell Res 2009, 315:2343-2357.
56. Fukai J., Nishio K., Itakura T., Koizumi K. Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III. Cancer Sci 2008, 99:2062-2069.